Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States

Manuela Di Fuscoa Health Economics & Outcomes Research, Pfizer Inc, New York, NY, USACorrespondence[email protected]

https://orcid.org/0000-0003-0079-7331

Kinga Marczellb Evidence, Value & Access by PPD, Evidera, Budapest, Hungary

Kristen A. Degerc Modeling and Simulation, Evidera, Bethesda, USA

Mary M. Morand Evidera PPD, Ivry-sur-Seine, France

Timothy L. Wiemkend Evidera PPD, Ivry-sur-Seine, France

Alejandro Canea Health Economics & Outcomes Research, Pfizer Inc, New York, NY, USA

Solène de Boisvilliersb Evidence, Value & Access by PPD, Evidera, Budapest, Hungary

Jingyan Yanga Health Economics & Outcomes Research, Pfizer Inc, New York, NY, USA;e Institute for Social and Economic Research and Policy, Columbia University, New York, NY, USA

Shailja Vaghelaf HEOR, HealthEcon Consulting, Inc, Ancaster, ON, Canada

Julie Roizg Evidence, Value & Access by PPD, Evidera, London, UK

show all

Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date